This drug, manufactured in India, should be postponed in individuals suffering from acute febrile illness/acute infection.
This authorization was given after the portfolio presented to the Mins will be analyzed and reviewed. Photo: Courtesy
The National Directorate of Pharmacy and Drugs of the Ministry of Health (Minsa) approved the emergency use of the Covaxin vaccine against the inactive SARS-CoV-2 whole virion coronavirus (BBV152).
This authorization was given after the portfolio presented to the Minsa will be analyzed and reviewed, detailing that Covaxin is indicated for active immunization against SARS-CoV-2 virus infection for young people over 18 years of age and The complete vaccination schedule for this product is two doses.
Administration of Indian-manufactured Covaxin should be postponed in individuals suffering from acute febrile illness/acute infection, while no data are available on the use of Covaxin in individuals who have previously received other viral vaccines.
The Ministry of Health reiterates to the population not to lower their guard and comply with the vaccination programs against COVID-19.
Sending Data…
